3 Finished Dosage Generics, Anti-Retroviral and Active Ingredient Leader and Complex Oncology Generics Stocks With a Strong Future Roadmap: Strides Pharma Science, Laurus Labs and Natco Pharma
- October 23, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Strides Pharma Science, Laurus Labs and Natco Pharma: ROE of 15.4% to 17.9% and FY22 to FY26 revenue CAGR of 8.5% to 21.0%. Prices as of 22 Oct 2026.
Quick Answer
The three US generics and complex oncology drug stocks to watch are Strides Pharma Science, Laurus Labs and Natco Pharma. Their return on equity ranges from 15.4% to 17.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.5% to 21.0%. Strides Pharma Science has the highest return on equity at 17.9%, while Natco Pharma has the fastest revenue growth at 21.0% a year. Prices are based on the 22 October 2026 close, and this article is educational, not investment advice.
US generics and complex oncology drug stocks let investors follow pharmaceutical companies that sell finished medicines in regulated markets. Strides Pharma Science, Laurus Labs and Natco Pharma cover finished dosage generics, an anti-retroviral and active ingredient leader and a maker of complex oncology generics.
This list covers three US generics and complex oncology drug stocks with complete current figures: Strides Pharma Science, Laurus Labs and Natco Pharma. Every figure comes from the latest reported financials and the 22 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are US Generics and Complex Oncology Drug Stocks?
US generics and complex oncology drug stocks are listed pharmaceutical companies that make generic formulations and active ingredients for regulated markets. Their earnings depend on approvals, launches and plant compliance.
US Generics and Complex Oncology Drug Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Strides Pharma Science | 1,025.3 | 9,491 | 15.0 | 36.0 | 17.9 | 0.57 |
| Laurus Labs | 2,012.5 | 111,434 | 102.2 | 36.0 | 16.8 | 0.48 |
| Natco Pharma | 785.15 | 15,708 | 13.7 | 36.0 | 15.4 | 0.08 |
On valuation, Strides Pharma Science and Natco Pharma trade at a P/E below the industry P/E, while Laurus Labs trades above it, which reflects the growth the market already expects. Readers comparing US generics and complex oncology drug stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do US Generics and Complex Oncology Drug Stocks Have a Strong Roadmap in India?
US generics and complex oncology drug stocks have a strong roadmap in India because global buyers keep turning to Indian makers for affordable medicines, and complex products earn better margins.
- Complex launches. Difficult-to-make generics face fewer competitors.
- Backward integration. Own ingredient supply supports cost and reliability.
- Regulated markets. Sales in the United States and Europe diversify earnings.
Why Strides Pharma Science Features Among These US Generics and Complex Oncology Drug Stocks
Among the US generics and complex oncology drug stocks on this list, Strides Pharma Science, based in Bengaluru, makes finished dosage generics for the United States and other regulated markets, with oral solids and soft gel capsules as important product groups.
The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0.
Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore.
Roadmap: The company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
What to watch: Track new US launches and the pace of price erosion in generic categories.
Why Laurus Labs Features Among These US Generics and Complex Oncology Drug Stocks
Among the regulated market pharma shares on this list, Laurus Labs is a Hyderabad-based pharmaceutical company with businesses in active ingredients, finished formulations, custom synthesis and biotechnology, with a leading position in anti-retroviral medicines.
Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 890 crore, a net margin of 13.0%.
In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore. The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0.
Roadmap: The company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.
What to watch: Follow the ramp-up of new capacity in formulations and the order flow in custom synthesis.
Why Natco Pharma Features Among These US Generics and Complex Oncology Drug Stocks
Among the three companies on this list, Natco Pharma is a Hyderabad-based pharmaceutical company focused on complex generics, oncology, and active ingredients, with a significant presence in the United States and other regulated markets.
Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%.
The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0.
Roadmap: The company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.
What to watch: Check the timing of key product launches in the US and the contribution from new drug approvals.
Strides Pharma Science vs Laurus Labs vs Natco Pharma on Key Financials
The table below sets the three US generics and complex oncology drug stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Strides Pharma Science | 3,202 | 5,009 | 11.8% | 575 | 11.5% |
| Laurus Labs | 4,951 | 6,868 | 8.5% | 890 | 13.0% |
| Natco Pharma | 2,044 | 4,376 | 21.0% | 1,372 | 31.4% |
Strides Pharma Science posts the highest return on equity in this group at 17.9%. Laurus Labs has the largest FY26 revenue at Rs 6,868 crore, and Natco Pharma shows the fastest revenue growth with a 21.0% compound annual rate. A useful habit with US generics and complex oncology drug stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in US Generics and Complex Oncology Drug Stocks
Every theme carries risks that deserve a check before any decision. For these US generics and complex oncology drug stocks, the main points are: Long-term regulated market pharma shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Pricing in export markets. Competition can weigh on generic prices.
- Regulatory checks. Plant inspections can delay launches.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter US generics and complex oncology drug stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on US Generics and Complex Oncology Drug Stocks
US generics and complex oncology drug stocks reward investors who follow approvals, launches and plant compliance together. Strides Pharma Science, Laurus Labs and Natco Pharma each have a clear pipeline. Based on the 22 October 2026 close, Strides Pharma Science trades at Rs 1,025.3, Laurus Labs at Rs 2,012.5 and Natco Pharma at Rs 785.15.
Download the Univest iOS App or Univest Android App to track US generics and complex oncology drug stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are US generics and complex oncology drug stocks?
Ans. US generics and complex oncology drug stocks are listed pharmaceutical companies that make generic formulations and active ingredients for regulated markets. Their earnings depend on approvals, launches and plant compliance. This list looks at three of them, Strides Pharma Science, Laurus Labs and Natco Pharma, using reported FY22 to FY26 financials and the 22 October 2026 closing prices.
Which US generics and complex oncology drug stocks are covered in this list?
Ans. This list covers Strides Pharma Science, Laurus Labs and Natco Pharma. Based on the 22 October 2026 close, Strides Pharma Science traded at Rs 1,025.3, Laurus Labs at Rs 2,012.5 and Natco Pharma at Rs 785.15. Their return on equity ranges from 15.4% to 17.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.5% to 21.0%.
Why do US generics and complex oncology drug stocks have a strong future roadmap in India?
Ans. US generics and complex oncology drug stocks have a strong roadmap in India because global buyers keep turning to Indian makers for affordable medicines, and complex products earn better margins. The main drivers are as follows. Complex launches. Difficult-to-make generics face fewer competitors. Backward integration. Own ingredient supply supports cost and reliability. Regulated markets. Sales in the United States and Europe diversify earnings. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Strides Pharma Science performed financially?
Ans. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
How has Laurus Labs performed financially?
Ans. Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 890 crore, a net margin of 13.0%. In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore. The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0. Looking ahead, the company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.
How has Natco Pharma performed financially?
Ans. Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.
What risks should investors check before buying US generics and complex oncology drug stocks?
Ans. Investors should check a few risks before buying US generics and complex oncology drug stocks. Pricing in export markets. Competition can weigh on generic prices. Regulatory checks. Plant inspections can delay launches. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of US generics and complex oncology drug stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 22 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
